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Abstract
Background: The natural course of sexually transmitted infections caused by Chlamydia trachomatis varies between
individuals. In addition to parasite and host effects, the vaginal microbiota might play a key role in the outcome of
C. trachomatis infections. Interferon-gamma (IFN-γ), known for its anti-chlamydial properties, activates the expression
of indoleamine 2,3-dioxygenase (IDO1) in epithelial cells, an enzyme that catabolizes the amino acid L- tryptophan
into N-formylkynurenine, depleting the host cell’s pool of tryptophan. Although C. trachomatis is a tryptophan
auxotroph, urogenital strains (but not ocular strains) have been shown in vitro to have the ability to produce
tryptophan from indole using the tryptophan synthase (trpBA) gene. It has been suggested that indole producing
bacteria from the vaginal microbiota could influence the outcome of Chlamydia infection.
Results: We used two in vitro models (treatment with IFN-γ or direct limitation of tryptophan), to study the effects
of direct rescue by the addition of exogenous indole, or by the addition of culture supernatant from indole-positive
versus indole-negative Prevotella strains, on the growth and infectivity of C. trachomatis. We found that only
supernatants from the indole-positive strains, P. intermedia and P. nigrescens, were able to rescue tryptophan-starved
C. trachomatis. In addition, we analyzed vaginal secretion samples to determine physiological indole concentrations.
In spite of the complexity of vaginal secretions, we demonstrated that for some vaginal specimens with higher
indole levels, there was a link to higher recovery of the Chlamydia under tryptophan-starved conditions, lending
preliminary support to the critical role of the IFN-γ-tryptophan-indole axis in vivo.
Conclusions: Our data provide evidence for the ability of both exogenous indole as well as supernatant from
indole producing bacteria such as Prevotella, to rescue genital C. trachomatis from tryptophan starvation. This adds
weight to the hypothesis that the vaginal microbiota (particularly from women with lower levels of lactobacilli and
higher levels of indole producing anaerobes) may be intrinsically linked to the outcome of chlamydial infections in
some women.
Keywords: Tryptophan-synthase, Interferon-γ, Microbiota
* Correspondence: Noa.Ziklo@research.usc.edu.au
1University of Sunshine Coast, 90 Sippy Downs Dr, Sippy Downs, Queensland
4556, Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ziklo et al. BMC Microbiology  (2016) 16:286 
DOI 10.1186/s12866-016-0903-4
Background
Chlamydia trachomatis is an obligate intracellular bacter-
ium with a unique biphasic developmental cycle. The cycle
begins with the uptake of the infectious elementary body
form (EB) by the host cell. The EB remains in a membrane-
bound vacuole termed an inclusion, where it differentiates
into the non-infectious, reticulate body form (RB). The RBs
undergo cell division. After 8–12 rounds of multiplication,
and inclusion growth, RBs asynchronously convert back to
the EB form [1, 2]. At 30–68 h post infection (PI), depend-
ing on the infecting strain, the EBs are released from the
host cell [3]. However, under stressful growth conditions
such as nutrient starvation, exposure to antibiotics or im-
mune factors such as interferon-gamma (IFN-γ) [4–6], the
chlamydial cycle is disturbed and the RBs convert to
enlarged, non-infectious, aberrant bodies (ABs) [1, 3, 7, 8].
Once the stress factor is removed, the Chlamydia revert to
the active developmental cycle [3, 8, 9].
Genital C. trachomatis infections remain a major health
problem. Worldwide, an estimated 131 million sexually
transmitted C. trachomatis infections occur each year [10].
In women, the severity of the infection as well as the prob-
ability to progress to complications varies among individ-
uals. Complications such as pelvic inflammatory disease
(PID) and infertility are common following C. trachomatis
infection [11–13] and may be associated with the partici-
pant’s inability to fully clear their infection, or a history of
repeat infections [13–16]. The proinflammatory cytokine
interferon-γ (IFN-γ) is known for its central role in inflam-
mation and autoimmunity [17]. This cytokine is
upregulated upon infection [18, 19] and has inhibitory
effects on C. trachomatis [19, 20]. IFN-γ has many effects
but for Chlamydia most significant appears to be the
induction of expression of the enzyme indoleamine
2,3-dioxygenase (IDO), in epithelial cells, that catalyses the
degradation of the essential amino acid, L-tryptophan into
N-formylkynurenine [21]. Depletion of the host cell trypto-
phan pools causes the Chlamydia, a tryptophan auxotroph,
to enter its persistent form [22], evident in vitro by
enlarged, aberrant bodies (ABs) (or die at severe depletion)
[5, 23]. When the tryptophan is restored, in vitro evidence
shows that the Chlamydia returns back to its infectious
state [24, 25]. While different chlamydial strains have a
range of sensitivity levels to IFN-γ treatment in vitro [9,
26], high concentrations are lethal. C. trachomatis genital
(D-L), but not ocular (A-C) strains, have a functional tryp-
tophan synthase gene (trpBA) [25–28], which enables them
to synthesise tryptophan from indole. Addition of exogen-
ous indole to the cell culture, can rescue the genital C. tra-
chomatis strains from IFN-γ exposure, enabling them to
subsequently produce infectious progeny [27, 29, 30].
In addition to the host immune response [16], C.
trachomatis infection risk is increased during episodes
of bacterial vaginosis (BV), which is characterized by
reduced levels of lactobacilli and a higher proportion of
anaerobic bacteria in the vaginal tract [31–34]. One
hypothesis described by Morrison et al. [35], suggested
that indole producing bacteria in the vaginal flora might
contribute to the survival of the Chlamydia by providing
a source of indole at the infection site [24, 27, 35–37]. In
this study, we directly investigated the effect of indole
producing bacteria, such as Prevotella, on C. trachomatis
recovery after tryptophan starvation. Our results show
that supernatant from indole producing Prevotella inter-
media and Prevotella nigrescens, but not indole negative
Prevotella bivia, can rescue C. trachomatis after trypto-
phan starvation in vitro. In addition, vaginal secretions
from five women had different effects on the recovery of
the Chlamydia after tryptophan starvation.
Methods
C. trachomatis in vitro culture conditions
The C. trachomatis isolates used in this study included: C.
trachomatis serotype D (ATCC VR-885), C. trachomatis
serotype C (ATCC VR-1477). Isolates were routinely cul-
tured in HEp-2 cell line (ATCC CCL-23) with DMEM
(Gibco, Australia) containing 5% heat inactivated fetal calf
serum (FCS) (Life Technologies, Australia), 120 μg/ml
streptomycin (Sigma-Aldrich, Australia), 50 μg/ml Genta-
mycin (Gibco, Australia), 37 °C, 5% CO2. All experiments
were conducted in 48-well plates at a multiplicity of infec-
tion (MOI) of 0.5. For the IFN-γ-induced tryptophan
starvations experiments; 25,000 cells/well were seeded
48 h before infection, in the presence of different concen-
trations of human IFN-γ (Peprotech, Australia). IFN-γ
treatment was replenished every 24 h until the rescue time
point. For the tryptophan-depleted media experiments
(Jomar Life Research, Australia), 50,000 cells/well were
seeded 24 h before infection. At the time of infection, the
HEp-2 monolayer was at around 90% confluence. Fresh
media and appropriate treatments were supplied to the
culture every 24 h and the infectious yields were measured
at 36/60/72 h PI (depends on the specific experiment- see
figures legend). Infected cells and culture supernatants
were then sonicated and used to infect a new HEp-2 cell
monolayer in three replicates, for enumeration of recover-
able inclusion forming units (IFUs). After staining with
anti-HtrA and goat anti rabbit IgG (H + L) Alexa Flour
488 (Invitrogen, Australia), wells were visualized for inclu-
sion presence using fluorescence microscopy (Nikon
Eclipse TiS Fluorescent Microscope) [38, 39]. The IFU/ml
were determined for each condition by measuring the
number of inclusions in multiple wells, taking into
account the dilution and volume from the original culture.
The limit of detection of the assay is 102 IFU/ml. Rescue
experiments using an IFN-γ-induced tryptophan starva-
tion model were conducted following three washes with
phosphate-buffered saline (PBS). Rescue experiments
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using tryptophan-depleted media were conducted with
the addition of tryptophan, indole, bacterial isolates super-
natant or cervical secretions, in the presence of cyclohexi-
mide, at 36 h PI and were incubated for further 36 h.
Control cultures with normal tryptophan supply, as well
as tryptophan-depleted conditions without rescue, were
included in all experiments. In all ‘No rescue’ treatments,
cultures were harvested to check chlamydial recovery at
36 h PI. Morphological observation of the chlamydial
inclusions in tryptophan-depleted media was made in sev-
eral of the treatments using Chlamydia LPS stain (Cellabs,
Australia) and visualised using confocal microscopy
(Nikon Eclipse Ti) (Additional file 1: Figure S1). For the
morphological observations, cultures were fixed with
methanol at 36 h PI (Additional file 1: Figure S1A), and at
72 h PI (Additional file 1: Figure S1B, C).
In vitro rescue of C. trachomatis with supernatant from
indole positive/negative bacteria
Indole producing bacteria, P. intermedia (ATCC 25611)
and P. nigrescens (ATCC 33563), and a non-indole pro-
ducing bacterium P. bivia (vaginal isolate), were cultured
in BHI broth 37 °C/36 h in anaerobic conditions. OD600
was measured and corrected for all strains to OD = 1. In-
dole production was confirmed using Kovac’s reagent
(Sigma-Aldrich, Australia). Bacterial broth was centri-
fuged 3000 × g/10 min/RT and supernatant was collected
and filter sterilised with 0.22 μM filter. Supernatant was
added to the tryptophan-deprived C. trachomatis in-
fected cell culture at 36 h PI. Infected cells and culture
supernatants were sonicated at 72 h PI and were used to
infect a new HEp-2 cell monolayer for enumeration of
recoverable IFUs.
RNA extraction and reverse transcription
C. trachomatis infected cell culture samples were stored
in RNAlater. Total RNA was extracted from the cells
using RNeasy mini kit (Qiagen, Australia), according to
the manufacturer’s instructions. The RNA concentration
and purity was determined using Nano-drop Spectropho-
tometer. 0.2 μg of total RNA was reverse transcribed using
QuantiTect Reverse transcription kit (Qiagen, Australia),
in accordance with the manufacturer’s instructions.
C. trachomatis trpBA transcript expression
The primers sequences were taken from Carlson et al.,
paper [30], with minor changes to complement C. tracho-
matis serotype D. Forward primer for trpBA amplification:
5′-GCATTGGAGTCTTCACATGC-3′, and reverse pri-
mer: ′3-ACACCTCCTTGAATCAGAGC-5′. Amplifica-
tion was carried out according to the manufacturer’s
instructions using QuntiNova SYBR Green PCR kit (Qia-
gen, Australia). The cycling program was 95 °C for 2 min
followed by 40 cycles of 5 s at 95 °C and 10 s at 60 °C.
Transcript levels were quantified using Rotor-GeneQ (Qia-
gen, Australia). Results were normalized against the mRNA
of C. trachomatis-specific ompA gene transcripts (using
previously described primers [40]) in each cDNA prepar-
ation. Results are presented as normalised values of 2-ΔΔCT.
Elution of vaginal secretions and Indole concentration
measurement
LASIK PVA eye sponges (Visitec) were placed in the
posterior fornix of the vagina for two min to absorb secre-
tions [41]. Sponges were immediately placed in −20 °C
until vaginal fluid was extracted the same day. Vaginal
fluid was eluted from sponges using 300 μl of PBS. Total
indoles were quantified using Salkowski’s test [42], modi-
fied as described by Szkop et al. [43]. Briefly, serial
dilutions of indole (Sigma-Aldrich, Australia) were used in
order to generate a standard curve by measuring absorb-
ance at 530 nm, following incubation with Salkowski’s
reagent. Indole concentrations were corrected for the
dilution factor of the samples.
Participant details and sample collection procedures
Samples were collected from a small study in
reproductive-age women who were either, negative for,
or infected with C. trachomatis, attending the sexual
health clinic in Nambour, Australia. All participants pro-
vided informed written consent to participate in the
study. Two Chlamydia negative and three Chlamydia
positive women were recruited to the study. Chlamydia
testing (positive/negative) was performed by the Nam-
bour STI Clinic. High vaginal swab sample and cervical
secretion sample were collected from each participant to
enumerate chlamydial infection load and indole concen-
tration. Participants’ secretion samples were evaluated
for their indole content as described above. Secretions
were added to the tryptophan-starved culture at 36 h PI
to evaluate the Chlamydia recovery effect. The secretions
were added in different dilutions; 1:100, 1:1000, 1:10,000,
as well as secretions at 1:10,000 dilution with the addition
of 0.5 μM indole (Additional file 2: Figure S2).
Statistical analyses
All cell culture experiments (Figs. 1, 2, 3, 4, 5 and 6) were
conducted in triplicate. The IFU/ml was determined for
each condition by measuring the number of inclusions in
multiple wells, and accounting for the dilution and vol-
ume from the original culture. Data were analysed using
Prism GraphPad V.6 and presented as the mean ± SD
IFUs (n = 9) determinations. Statistical significance in Fig. 6
was determined using two-way ANOVA and p- values
were calculated using Tukey’s multiple comparison test.
For Fig. 4 statistical significance was determined via
multiple t testing using the Holm-Sidak method, with
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alpha = 0.05, while each row was analyzed individually,
without assuming a consistent SD.
Results
IFN-γ- induced tryptophan starvation and rescue
We first established an in vitro assay using IFN-γ treated
HEp-2 cells, infected with either C. trachomatis genital
(serovar D) or ocular (serovar C) strains, and demon-
strated different abilities of these strains to recover
following the addition of tryptophan (fresh ‘DMEM’) or
indole (10 μM) (Fig. 1), after IFN-γ treatment. HEp-2
cells were infected with C. trachomatis and incubated in
the presence of different IFN-γ concentrations (0, 150,
500 U/ml) for 36 h. At the time of recovery; 36 h PI,
without rescue (‘No rescue’ treatment), no inclusions
were detected. Consistent with the literature, our data
showed that both strains were able to recover from IFN-
γ treatment (36 h) when the IFN-γ was removed and
replaced with fresh DMEM containing 78.3 μM (16 mg/L)
L-tryptophan (as per the manufacturer’s description). For
C. trachomatis D, treatment with 500 units of IFN-γ
resulted in no remaining infectious organisms but when
fresh DMEM was added, 4.9 × 103 IFUs/ml were recov-
ered. The ocular strain, C, showed 1.2 × 102 IFU/ml
recovery under similar conditions. When exogenous
indole (rather than DMEM containing exogenous trypto-
phan) was used for the recovery step, the genital strain D
showed a very high (2.1 × 105) recovery of IFUs/ml, as
there was no competition from the host cell for indole,
whereas the ocular strain C did not show any additional
Fig. 1 Recovery of IFN-γ treated C. trachomatis (ocular; C and genital; D strains), with tryptophan (DMEM) and indole (10 μM). Monolayers of HEp-2
cells were seeded 48 h before infection in the presence of different IFN-γ concentrations (0, 150, 500 U/ml). IFN-γ treatment was replenished every
24 h throughout the whole experiment. Cells were infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 h. The Chlamydia
infected cultures were allowed to recover for 24 h in the presence of tryptophan (DMEM) or indole (10 μM). Infected cells and culture supernatants
were sonicated and used to infect a new HEp-2 cell monolayer for enumeration of recoverable IFUs. Data are presented as the mean ± SD IFU/ml
(n = 9) determinations
Fig. 2 Effect of different indole concentrations on the recovery of C. trachomatis D following IFN-γ treatment. Monolayers of HEp-2 cells were seeded
48 h before infection in the presence of different IFN-γ concentrations (0, 150, 500 U/ml). IFN-γ treatment was replenished every 24 h throughout the
whole experiment. Cells were infected with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 h. The Chlamydia infected cultures were
allowed to recover for 24 h with different indole concentrations (0.1, 0.25, 0.5, 1 μM). Infected cells and culture supernatants were sonicated and used
to infect a new HEp-2 cell monolayer for enumeration of recoverable IFUs. Data are presented as the mean ± SD IFU/ml (n = 9) determinations
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recovery (compared to DMEM alone). Next, we investi-
gated a range of exogenous indole concentrations on recov-
ery and found that levels of 0.25 μM and higher resulted in
high levels of recovery, even when the cultures were origin-
ally treated with 1000 units/ml of IFN-γ (Fig. 2).
C. trachomatis D recovery using tryptophan or indole in a
tryptophan-depleted media model
The model of C. trachomatis inhibition using IFN-γ, cul-
tured with DMEM, is problematic, as the media contains
large amounts of tryptophan. Therefore, we used a model
using tryptophan-depleted media, and added increasing
concentrations of tryptophan or indole at 36 h PI to
rescue the C. trachomatis D from tryptophan starvation
(Fig. 3a, b). Exogenous levels of tryptophan were able to
effectively rescue the Chlamydia, with a maximum level
of recovery of 2 × 104 IFU/ml, while there was no compe-
tition from the host cell over the tryptophan, as the
cultures were treated with cycloheximide (Fig. 3a). Indole
rescue on the other hand, showed a maximum recovery
level of 7.6 × 104 IFU/ml with concentration dependent
increase in the Chlamydia infectivity after tryptophan
starvation (Fig. 3b). When no rescue treatment was used,
there were no inclusions detected at 72 h PI (“No rescue”),
Fig. 3 Recovery of tryptophan-starved C. trachomatis strain D after rescue with exogenous tryptophan (122–980 μM) or indole (0.1–10 μM). Monolayers
of HEp-2 cells were seeded in the presence of tryptophan-depleted media 24 h before infection. Cells were infected with C. trachomatis D, at an MOI
of 0.5, and were incubated for 36 h. The Chlamydia infected cultures were allowed to recover for 36 h with increasing concentrations of tryptophan (a)
or indole (b). Infected cells and culture supernatants were sonicated and used to infect a new HEp-2 cell monolayer for enumeration of recoverable
IFUs. Data are presented as the mean ± SD IFU/ml (n = 9) determinations
Fig. 4 Recovery of tryptophan-starved C. trachomatis strain D after rescue with supernatant from indole positive/indole negative bacteria. Monolayers of
HEp-2 cells were seeded in the presence of tryptophan-depleted media 24 h before infection. Cells were infected with C. trachomatis D, at an MOI of 0.5,
and were incubated for 36 h. The Chlamydia infected cultures were allowed to recover for 36 h in the presence of (a) supernatant from indole producing
P. intermedia and P. nigrescens, and a non-indole producer P. bivia. Data are presented in dilution of 1:10,000. P. bivia is significantly different (p < 0.0001).
Indole concentrations measured from the growth medium of P. intermedia and P. nigrescens were 300 μM and 250 μM respectively. b A control of the
bacterial growth broth (BHI) was added as well. All treatments were added in different dilutions of 1:1000, 1:5000 and 1:10,000 (Additional file 3: Figure S3).
Infected cells and culture supernatants were sonicated and used to infect a new HEp-2 cell monolayer for enumeration of recoverable IFUs. Data are
presented as the mean ± SD IFU/ml (n= 9) determinations. Statistical significance determined via multiple t testing using the Holm-Sidak method, with
alpha = 0.05. Each row was analyzed individually, without assuming a consistent SD
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as well as at the time of reactivation of the cultures; 36 h
PI (data not shown).
C. trachomatis rescue using indole-producing bacterial
supernatants
In order to investigate whether supernatant from indole
producing bacteria could rescue Chlamydia, we chose
two indole producing Prevotella spp. (P. intermedia and
P. nigrescens) and one indole-negative strain, P. bivia.
The bacteria were incubated in brain heart infusion
(BHI) medium for 36 h. As the BHI growth medium
contains tryptophan, we included the medium alone as a
control and tested it at a range of dilutions (1:1000,
1:5000, and 1:10,000). Only supernatant from the indole-
positive bacteria (P. intermedia and P. nigrescens) were
able to rescue the Chlamydia at the critical dilution of
1:10,000 (Fig. 4) (p value < 0.0001 relative to BHI). By
comparison, P. bivia, which is indole negative, was not
able to rescue the Chlamydia at the same dilution (p value
< 0.0001 relative to P. bivia). When no rescue treatment
was used, there were no inclusions detectable, at 72 h PI, as
well as at the time of reactivation of the cultures; 36 h PI
(data not shown).
C. trachomatis rescue using vaginal secretions from
Chlamydia positive and Chlamydia negative women
We utilised a combination of in vitro and ex vivo model
to test the hypothesis that some of the vaginal indole-
producing microbiota may counteract the immune
system response mediated by IFN-γ, by providing a
source of indole and allows the Chlamydia to survive
under tryptophan-depleted conditions. Specifically, we
tryptophan-starved the C. trachomatis D strain using
tryptophan-depleted media. We then wanted to deter-
mine if vaginal secretions from different women was
able to rescue the infectivity of Chlamydia to differing
degrees, perhaps related to indole levels in these secre-
tions. We therefore evaluated the Chlamydia recovery of
infectivity compared with the participants’ chlamydial
status (positive/negative) and the amount of indole in
the vaginal secretions. The indole concentrations from
the participants’ secretions (indicated in Fig. 5), ranged
Fig. 5 Recovery of tryptophan-starved C. trachomatis strain D after
rescue with secretions from five (Chlamydia positive/negative)
participants that have different concentrations of indole in their vaginal
secretions. Monolayers of HEp-2 cells were seeded in the presence of
tryptophan-depleted media 24 h before infection. Cells were infected
with C. trachomatis D, at an MOI of 0.5, and were incubated for 36 h.
The Chlamydia infected cultures were allowed to recover for 36 h in
the presence of secretions from two C. trachomatis negative participants
(111 and 112) and three C. trachomatis positive participants (213, 211
and 306). Chlamydia test (CT+/CT-), pH and BV conditions are indicated
in boxes above each participant. Secretions were added to the cultures
at dilution of 1:100. Axis X represent the indole concentrations measured
from the participants’ secretions, axis Y represent the recovery effect of
the Chlamydia in IFU/ml. Infected cells and culture supernatants were
sonicated and used to infect a new HEp-2 cell monolayer for enumeration
of recoverable IFUs. Data are presented as the mean± SD IFU/ml
(n=9) determinations
Fig. 6 RT-qPCR quantitation of trpBA gene mRNA, isolated from HEp-2 cells, infected with C. trachomatis strain D during tryptophan starvation conditions
and rescue. C. trachomatis infected cultures and conditions were as described in the legend of Figs. 4 and 5. a Total RNA was isolated from infected
cultures grown in tryptophan-depleted media at 72 h PI (‘No rescue’), and after indole rescue in different concentrations (0.5, 5 μM), as well as complete
DMEM conditions harvested at 36 and 72 h PI (‘DMEM’). No rescue treatment is significantly different p< 0.0001. b trpBA transcript levels were measured
from rescue treatments of infected cultures using indole positive bacterial supernatant (P. intermedia, P. nigrescens) and indole negative (P. bivia), applied in
dilution of 1:10,000. P. bivia is significantly different p< 0.005
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from 2.18 to 7.35 mM. Participant’s vaginal secretions
were added to the C. trachomatis infected culture after
tryptophan starvation for 36 h PI. We found higher
recovery levels of the Chlamydia following rescue with
secretions from participants 111 and 211 with relatively
high indole concentrations (4.76 mM and 6.06 mM
respectively) (Fig. 5). However, using secretions from
participant 112 and 213 (who had relatively low indole
concentrations in their secretions of 2.18 mM and
3.74 mM respectively), resulted in lower recovery of the
C. trachomatis after tryptophan starvation in vitro (2 ×
103 and 1.6 × 103 IFU/ml respectively). Across all five
participants there was no linear correlation of indole
and chlamydial recovery, however, four of the five partic-
ipants were consistent with a trend of higher indole
resulting in higher chlamydial infection. Spiking the
participants’ secretions with 0.5 μM indole (at dilution
of ‘1:10,000 + ’), eliminated some of the differences in
the Chlamydia recovery that were found between the
participants (at dilution of 1:100) (Additional file 3:
Figure S3). No significant differences were observed be-
tween participant’s secretions treatments in dilutions
1:1000 and 1:10,000 (Additional file 3: Figure S3). When
no rescue treatment was used, there were no inclusions
detected, at 72 h PI, as well as at the time of reactivation
of the cultures; 36 h PI (data not shown).
trpBA gene expression in tryptophan-starved C. tracho-
matis D following different rescue conditions
In an attempt to gain further support for the hypothesis,
that the response of the tryptophan-starved C. tracho-
matis to the availability of tryptophan and indole (added
as a rescue treatment 36 h PI) involves their tryptophan
biosynthesis genes, we measured the mRNA expression
levels of the trpBA gene in our indole-producing bacter-
ial supernatant model (Fig. 6). Tryptophan starvation
was shown to induce trpBA transcription levels in C.
trachomatis culture (‘No rescue 72 h PI’. Fig. 6a). When
exogenous tryptophan is provided via the DMEM
medium, trpBA levels are switched off. (as expected),
and hence any evidence of trpBA expression indicates a
tryptophan starvation state of the Chlamydia. When
exogenous indole was provided (at 0.5 and 5 μM), the
trpBA gene expression levels were again increased to
some extent, presumably to convert the indole to more
tryptophan. (Fig. 6a). We then assessed the effect of add-
ing bacterial supernatants (at various dilutions) to the
chlamydial cultures and found that for P. bivia (indole
negative) the chlamydial trpBA expression was high,
confirming that they were tryptophan-starved (Fig. 6b).
By comparison, the trpBA levels for the two indole posi-
tive bacteria (P. intermedia and P. nigrescens) were
significantly lower (p value <0.05).
Discussion
In this study, we investigated the role of indole in the
recovery of urogenital C. trachomatis infections follow-
ing tryptophan starvation in vitro. The current hypoth-
esis argues that the availability of indole in the lower
genital tract site of women infected with C. trachomatis,
can influence the level and outcome of the infection.
Using both the established IFN-γ model as well as a
tryptophan-depleted media model, we found that super-
natants from the indole-positive bacteria, P. intermedia
and P. nigrescens, but not indole-negative P. bivia, were
able to recover C. trachomatis D infectivity when added
to the cultures at dilution of 1:10,000. Although there is
a range of bacterial products being produced by indole-
positive bacteria cultured in broth medium, we assume
that indole is a critical compound, which directly have a
positive effect on C. trachomatis recovery after trypto-
phan starvation in vitro. Treatment with supernatant of
indole-negative P. bivia and the control (BHI) were not
sufficient to rescue the Chlamydia using the same dilu-
tion of 1:10,000. Because the amount of bacteria in a
growth medium and the concentration of cytotoxic com-
pounds are much higher than the levels found in vivo,
we diluted the bacterial supernatants (1:1000, 1:5000 and
1:10,000). We also included a control of the bacterial
growth broth (BHI). We have tested the BHI medium
for tryptophan concentration, using commercial trypto-
phan ELISA kit (ImmuSmol, France), in order to validate
our conclusion from this experiment. BHI medium con-
tains 35 μg/ml (0.17 μM) tryptophan and therefore, it
might have affected the recovery levels of the
tryptophan-starved Chlamydia culture. However, when
diluting the BHI medium to 1:10,000, the tryptophan in
the medium itself was reduced to 3.5 ng/ml, which was
previously shown to be insufficient for the recovery of
Chlamydia after tryptophan starvation [22, 29]. Accord-
ingly, BHI rescue treatment at a dilution of 1:1000 had
significantly lower recovery compared to P. intermedia
at the same dilution (p value <0.005, suggesting that in-
dole in the P. intermedia supernatant had a beneficial ef-
fect, resulting in higher Chlamydia recovery in compare
to the BHI control (Additional file 3: Figure S3).
Indole concentrations measured from the growth
medium of P. intermedia and P. nigrescens were 300 μM
and 250 μM respectively. When diluting the supernatant
1:1000, the indole concentration was decreased to 0.25–
0.3 μM (Additional file 2: Figure S2). However, treat-
ment with the indole-positive bacterial supernatant at
this dilution, resulted in significantly higher recovery of
the Chlamydia (P. intermedia: 6.8 × 104 IFU/ml, P.
nigrescens: 3.1 × 104 IFU/ml) (p < 0.0001), in comparison
to the control in which exogenous indole was directly
added to a level of 0.5 μM (3.8 × 103 IFU/ml; Additional
file 2: Figure S2). This suggests again that the recovery
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effect from the bacterial supernatant may be further
increased as a result of the tryptophan content in the
media, in addition to the indole produced by the indole-
positive Prevotella.
Measurements of the chlamydial trpBA were
conducted in order to confirm our recovery data during
the different bacterial supernatant rescue treatments.
Significantly higher expression levels in P. bivia super-
natant rescue, suggested that there was no recovery of
the tryptophan-starved Chlamydia via exogenous in-
dole/tryptophan addition. This confirms our assumption
that a non-indole producing bacterium such as P. bivia,
is not able to rescue the Chlamydia after tryptophan
starvation. trpBA measurements in indole positive
bacterial supernatants (Fig. 6b) indicated lower expres-
sion levels in comparison to the tryptophan-starved
Chlamydia (‘No rescue 72 h PI’; Fig. 6a), probably
caused by the presence of indole in the media.
In order to investigate whether differences in the indole
content in vaginal secretions of women who are negative
for, or infected with C. trachomatis, have different effects
on tryptophan-starved C. trachomatis recovery in vitro,
we used the same tryptophan-depleted media model. We
found that low indole content in secretions from partici-
pants 112 and 213 corresponded with lower Chlamydia
recovery indicated by IFU/ml. Higher indole concentra-
tion in secretions from participants 111 and 211 corre-
sponded with a higher Chlamydia recovery effect at a
dilution of 1:100. This might suggest that high indole con-
centrations in the women’s secretions contribute to higher
recovery of the tryptophan-starved C. trachomatis culture
in vitro. C. trachomatis-positive participants 211 and 306
had considerably higher levels of indole in their secretions
(7.35 mM and 6.6 mM respectively). This could indicate a
link between Chlamydia infection status (positive/nega-
tive) and the indole concentrations measured from their
genital secretions.
Individuals vary in their susceptibility to C. trachoma-
tis infections, both new infections, as well as repeat
infections [44–46]. While there are many factors that
might contribute to this variation, such as individual
sexual patterns [46], innate and adaptive immune
response [47], the expression and release of the key cyto-
kine IFN-γ [23], one additional factor that might
influence this infection variation is the composition of
the vaginal microbiome [33, 48, 49]. In most healthy
women, lactobacilli are numerically dominant in the
lower genital tract, providing protection against a range
of pathogenic bacteria and resulting in a lower pH in
this environment [50–53]. The replacement of lactoba-
cilli by fastidious anaerobes, such as Prevotella spp., can
result in higher pH, dysbiosis and bacterial vaginosis
(BV) [48, 54]. It is well known that women with BV have
a higher risk of acquiring sexually transmitted infections
such C. trachomatis [33, 55, 56]. Some of these BV asso-
ciated Prevotella are also indole positive, although this
balance may well be quite different between different in-
dividuals. Indole production in the lower genital tract
can also be associated with higher pH and lower num-
bers of lactobacilli. Our data clearly show that super-
natant from indole positive but not indole negative
Prevotella strains can rescue C. trachomatis from trypto-
phan starvation, in this in vitro model. It is possible that
other indole-producing bacteria (e.g. Porphyromonas
gingivalis, Propionibacterium acnes, Fusobacterium
nucleatum, Escherichia coli or Enterococcus faecalis)
which have been reported to colonize the genital tract in
dysbiosis, could have a similar effect. If this hypothesis is
confirmed, it opens up additional means of therapy for
women who get frequent C. trachomatis infections. Such
therapies might include probiotics and other interven-
tions to the vaginal microbiota in order to restore a
healthy, acidic, lactobacilli dominant environment.
Conclusions
Our results give further support to the hypothesis that
some members of the genital microbiota, such as Prevo-
tella, are able to produce indole and this might influence
the natural course of C. trachomatis infection in women,
by providing a substrate for the Chlamydia to produce
tryptophan, which enables them to escape the host’s
IFN-γ-mediated immune response. We demonstrated
that supernatants from indole-producing bacteria were
efficient in assisting the recovery of the Chlamydia after
tryptophan starvation in vitro, in comparison to non-
indole producers. By directly testing vaginal secretions
from a range of women, we found that higher levels of
indole in the vaginal secretions from some women con-
tributed to the recovery of tryptophan-starved C. tracho-
matis culture in vitro. Thus for the first time we have
provided ex vivo evidence that indole production in the
vagina might have a key role in the outcome of genital
Chlamydia infections and could lead to the development
of novel therapies.
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